Genesystem Co., Ltd. Share Price

Equities

A363250

KR7363250002

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. 03:30:00 07/05/2024 am IST 5-day change 1st Jan Change
6,020 KRW -0.17% Intraday chart for Genesystem Co., Ltd. -2.90% -35.48%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2021 13.24B 9.76M 814M Sales 2022 3.65B 2.69M 225M Capitalization 58B 42.75M 3.57B
Net income 2021 3.55B 2.62M 218M Net income 2022 -9B -6.63M -553M EV / Sales 2021 3.42 x
Net cash position 2021 33.5B 24.69M 2.06B Net cash position 2022 22.39B 16.5M 1.38B EV / Sales 2022 9.75 x
P/E ratio 2021
20.7 x
P/E ratio 2022
-6.42 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 76.03%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.17%
1 week-2.90%
Current month-1.95%
1 month-20.26%
3 months-12.24%
6 months-57.61%
Current year-35.48%
More quotes
1 week
5 900.00
Extreme 5900
6 230.00
1 month
5 900.00
Extreme 5900
7 840.00
Current year
5 390.00
Extreme 5390
11 580.00
1 year
5 390.00
Extreme 5390
32 000.00
3 years
4 970.00
Extreme 4970
32 000.00
5 years
4 970.00
Extreme 4970
32 000.00
10 years
4 970.00
Extreme 4970
32 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 01/13/01
Chief Tech/Sci/R&D Officer - -
Director/Board Member 66 -
Members of the board TitleAgeSince
Director/Board Member 66 -
Chief Executive Officer 55 01/13/01
Director/Board Member 54 01/17/01
More insiders
Date Price Change Volume
07/24/07 6,020 -0.17% 54 763
03/24/03 6,030 +0.17% 69,082
02/24/02 6,020 -1.95% 63,108
30/24/30 6,140 -0.97% 49,950

End-of-day quote Korea S.E., May 07, 2024

More quotes
GeneSystem Co Ltd is a Korea-based company principally engaged in the development and manufacture of molecular diagnostic solutions. The Company is engaged in the development, manufacture and sale of platform based on molecular diagnosis. The Company develops and manufactures products such as molecular diagnosis systems, biochips, test kits, and reaction reagents, among others. The Company develops in vitro diagnostic technology through immunodiagnosis technology and molecular diagnosis technology.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. A363250 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW